Dizal (Jiangsu) Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Dizal (Jiangsu) Pharmaceutical's earnings have been declining at an average annual rate of -16%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 75.1% per year.
Key information
-16.0%
Earnings growth rate
-11.9%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 75.1% |
| Return on equity | -212.3% |
| Net Margin | -214.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Dizal (Jiangsu) Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 390 | -837 | 563 | 790 |
| 30 Jun 24 | 295 | -938 | 521 | 840 |
| 31 Mar 24 | 173 | -1,092 | 471 | 849 |
| 31 Dec 23 | 91 | -1,108 | 438 | 801 |
| 30 Sep 23 | 40 | -1,055 | 365 | 759 |
| 30 Jun 23 | 0 | -905 | 274 | 675 |
| 31 Mar 23 | 0 | -794 | 198 | 649 |
| 31 Dec 22 | 0 | -736 | 128 | 661 |
| 30 Sep 22 | 4 | -714 | 107 | 657 |
| 30 Jun 22 | 7 | -716 | 96 | 656 |
| 31 Mar 22 | 10 | -716 | 92 | 633 |
| 31 Dec 21 | 10 | -670 | 88 | 584 |
| 30 Sep 21 | 11 | -593 | 78 | 501 |
| 31 Dec 20 | 28 | -587 | 340 | 424 |
| 31 Dec 19 | 41 | -446 | 47 | 409 |
| 31 Dec 18 | 39 | -174 | 33 | 197 |
Quality Earnings: 688192 is currently unprofitable.
Growing Profit Margin: 688192 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688192 is unprofitable, and losses have increased over the past 5 years at a rate of 16% per year.
Accelerating Growth: Unable to compare 688192's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688192 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.08%).
Return on Equity
High ROE: 688192 has a negative Return on Equity (-212.33%), as it is currently unprofitable.